Evidence map›Paper›PMID 34580162›Full record

ArticleJournal for immunotherapy of cancer2021

Eosinophilic features in clear cell renal cell carcinoma correlate with outcomes of immune checkpoint and angiogenesis blockade.

Takashi Yoshida, Chisato Ohe, Junichi Ikeda, Naho Atsumi, Haruyuki Ohsugi, Motohiko Sugi, Koichiro Higasa, Ryoichi Saito, Koji Tsuta, Tadashi Matsuda and 1 more

Abstract read
In one paragraph

Article in Journal for immunotherapy of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Takashi YoshidaDepartment of Urology and Andrology, Kansai Medical University, Osaka, Japan yoshidtk@takii.kmu.ac.jp.ORCID 0000-0003-1119-312X
Chisato OheDepartment of Pathology and Laboratory Medicine, Kansai Medical University, Osaka, Japan.
Junichi IkedaDepartment of Pathology and Laboratory Medicine, Kansai Medical University, Osaka, Japan.
Naho AtsumiDepartment of Pathology and Laboratory Medicine, Kansai Medical University, Osaka, Japan.
Haruyuki OhsugiDepartment of Urology and Andrology, Kansai Medical University, Osaka, Japan.
Motohiko SugiDepartment of Urology and Andrology, Kansai Medical University, Osaka, Japan.
Koichiro HigasaGenome Analysis, Institute of Biomedical Science, Kansai Medical University, Osaka, Japan.
Ryoichi SaitoDepartment of Urology and Andrology, Kansai Medical University, Osaka, Japan.ORCID 0000-0002-3163-8723
Koji TsutaDepartment of Pathology and Laboratory Medicine, Kansai Medical University, Osaka, Japan.
Tadashi MatsudaDepartment of Urology and Andrology, Kansai Medical University, Osaka, Japan.
Hidefumi KinoshitaDepartment of Urology and Andrology, Kansai Medical University, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundClear cell renal cell carcinoma (ccRCC) displays heterogeneity in appearance-a distinctive pale clear to eosinophilic cytoplasm; however, little is known about the underlying mechanisms and clinical implications. We investigated the role of these eosinophilic features in ccRCC on oncological outcomes and response to tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs).

methodsOne-hundred and thirty-eight ccRCC cases undergoing radical surgery (cohort 1) and 54 metastatic ccRCC cases receiving either TKIs or ICIs (cohort 2) were included. After histological evaluation, all cases were divided into three phenotypes based on the eosinophilic features at the highest-grade area: clear, mixed, or eosinophilic type. Gene expression and immunohistochemical analyses were performed to explore the potential mechanisms of these phenotypes in cohort 1. Further, the association of the three phenotypes with the best objective response to TKI or ICI, clinical benefit (complete/partial response or stable disease), and overall survival (OS) was assessed in cohort 2.

resultsThe clear type was significantly associated with increased hypoxia as well as angiogenesis gene signatures compared with the eosinophilic type. Gene signatures and protein expression related to effector T cell and immune checkpoint molecules were elevated to a greater extent in the eosinophilic type, followed by the mixed and clear types. The mixed and eosinophilic types exhibited greater PBRM1-negativity and increased prevalence of the epithelial-mesenchymal transition gene signature than the clear type. In the mixed/eosinophilic types of cohort 2, significant clinical benefit was observed in the ICI therapy group versus the TKI therapy group (p=0.035), and TKI therapy vs ICI therapy was an independent factor for worse prognosis of OS (HR 3.236; p=0.012).

conclusionThe histological phenotype based on the eosinophilic features, which are linked to major immunological mechanisms of ccRCC, was significantly correlated with therapeutic efficacy.

Indexed as

AgedCarcinoma, Renal CellEosinophilsFemaleHumansImmune Checkpoint InhibitorsKidney NeoplasmsMaleMiddle AgedProtein Kinase InhibitorsImmune Checkpoint InhibitorsProtein Kinase Inhibitorsbiomarkersimmunohistochemistryimmunotherapykidney neoplasmsneovasularizationpathologictumor

Identifiers

PMID34580162
PMCPMC8477329

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.